Argatroban - Eagle Pharmaceuticals

Drug Profile

Argatroban - Eagle Pharmaceuticals

Alternative Names: Pre-mixed argatroban; Ready-to-use argatroban

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator Eagle Pharmaceuticals
  • Class Antithrombotics; Pipecolic acids; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heparin-induced thrombocytopenia and thrombosis syndrome

Most Recent Events

  • 22 Jun 2016 Chiesi USA and Chiesi Farmaceutici acquired multinational rights to Argatroban from The Medicines Company
  • 12 Sep 2011 Launched for Heparin-induced thrombocytopenia and thrombosis syndrome in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top